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Aims. Insulin dependent diabetes mellitus (IDDM) is believed to be an autoimmune disorder with disturbed glucose/insulin
metabolism, requiring life-long insulin replacement therapy (IRT), 30% of patients develop end-organ failure. We present our
experience of cotransplantation of adipose tissue derived insulin-secreting mesenchymal stem cells (IS-AD-MSC) and cultured
bone marrow (CBM) as IRT for these patients. Methods. This was a prospective open-labeled clinical trial to test eﬃcacy
and safety of IS-AD-MSC+CBM co-transplantation to treat IDDM, approved by the institutional review board after informed
consent in 11 (males : females: 7 : 4) patients with 1–24-year disease duration, in age group: 13–43 years, on mean values
of exogenous insulin requirement of 1.14 units/kgBW/day, glycosylated hemoglobin (Hb1Ac): 8.47%, and c-peptide levels:
0.1ng/mL. Intraportal infusion of xenogeneic-free IS-AD-MSC from living donors, subjected to deﬁned culture conditions and
phenotypically diﬀerentiated to insulin-secreting cells, with mean quantum: 1.5mL, expressing Pax-6, Isl-1, and pdx-1, cell
counts: 2.1 × 103/μL, CD45−/90+/73+:40/30.1%, C-Peptide level:1.8ng/mL, and insulin level: 339.3 IU/mL with CBM mean
quantum: 96.3mL and cell counts: 28.1 × 103/μL, CD45−/34+:0.62%, was carried out. Results. All were successfully transplanted
without any untoward eﬀect. Over mean followup of 23 months, they had a decreased mean exogenous insulin requirement
to 0.63units/kgBW/day, Hb1Ac to 7.39%, raised serum c-peptide levels to 0.38ng/mL, and became free of diabetic ketoacidosis
eventswithmean2.5Kgweightgainonnormalvegetariandietandphysicalactivities.Conclusion.Thisistheﬁrstreportoftreating
IDDM with insulin-secreting-AD-MSC+CBM safely and eﬀectively with relatively simple techniques.
1.Introduction
The incidence of diabetes mellitus (DM) has been increasing
in an epidemic-like fashion in the last two decades globally.
India is expected to become the world capital of DM by year
2030 [1–3]. Insulin dependent diabetes mellitus (IDDM)
is the second most common chronic disease of childhood
believed to be autoimmune in nature and characterized
by irreversible destruction of insulin-secreting pancreatic β
islet cells. Symptoms of the disease appear when insulin-
making β cell mass gets reduced by approximately 90%
leading to severe insulin deﬁciency and hyperglycemia.
At present the only therapeutic options for management
are life-long exogenous insulin preparations. Sporadic
reports of autologous hematopoietic stem cell transplan-
tation (HSCT) have been reported with limited success
[4].
We present our experience of insulin replacement ther-
apy (IRT) by co-transplantation of insulin-secreting adipose
tissue derived mesenchymal stem cells (IS-AD-MSC) and
cultured-bone-marrow- (CBM-) derived HSCT in 11 IDDM
patients.2 Stem Cells International
2. Study Design(Figure1)
This was a prospective nonrandomized open-label clinical
trial conducted from October 2007 to September 2008 to test
the eﬃcacy and safety of combined IS-AD-MSC and HSCT
as IRT in IDDM patients. HSC co-transplantation with IS-
AD-MSC was designed to augment the eﬀect of the later.
Omentalvein infusion was carried out so that the cells would
get trapped in hepatic microcirculation and the liver, being
tolerogenic organ, would not reject them. The institutional
Review Board approved of consent forms and clinical trial.
Inclusion criteria were patients between 5 to 45 years of
age, of any gender, with conﬁrmed diagnosis of IDDM at
least for 6 months, with low levels of serum C-peptide levels
(<0.5ng/mL).
ExclusioncriteriawerepositiveserologyforHIV/HbSAg/
HCV and underlying hematologic, nephrologic, cardiac,
psychiatric, or hepatic diseases, and pregnancy.
Healthy nondiabetic donors from family of recipients
having matching blood group with patients, who were
willing to donate fat and bone marrow (BM) were approved
as donors in this research protocol after their informed
written consent.
3. Methods
3.1. Adipose Tissue and BM Procurement from Donor. Adi-
pose tissue (approximately 2gm) was resected from anterior
abdominal wall of donors on day −14, sutures taken after
hemostasis were achieved and sent to stem cell lab for
culture in appropriate transport medium to derive MSC and
further diﬀerentiate them into insulin-secreting cells. On
days −10 and −9, donors were stimulated with injection
granulocyte colony-stimulating Factor (G-CSF), 7.5μg/kg
BW/ day subcutaneously followed by BM aspiration from
their posterior superior iliac crest under local anesthesia, in
which 60mL BM was collected on day −8.
3.2. Isolation of MSC from Adipose Tissue. The resected
adipose tissue was transported to the lab in self-designed
proliferation medium with Dulbecco’s modiﬁed eagle’s
medium (DMEM, Sigma, USA) (high glucose), 20% human
albumin (Reliance Life Sciences, India), Fibroblast growth
factor: 2ng/mL, 1% Sodium pyruvate, and appropriate
antibiotics which included penicillin, streptomycin, cefo-
taxime,andﬂuconazolandmincedwithknifeintotinypieces
in Collagenase type I (10mg/10mL) solution. The entire
contents of the medium were processed in culture dish and
after mincing they were placed in incubator at 37◦Cw i t h
shaker arranged with 35RPM for 1 hour, and subsequently
transferred to 15mL centrifuge tubes and centrifuged at
780RPM for 8 minutes. After centrifugation the supernatant
and pellets were separately cultured in proliferation medium
on 100sq.cm and 25sq.cm cell+ plates (Sarstedt, USA),
respectively, at 37◦C with 5% CO2 under humid conditions
for 10 days. Medium was replenished every other day.
3.3. Culture and Diﬀerentiation of h-AD-MSC into Insulin-
Secreting Cells. On the 10th day of culture in proliferation
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Figure 1: Ahmedabad paradigm of Cotransplantation of insulin
secreting and hematopoietic stem cells for IDDM.
medium, the cells were washed in phosphate buﬀered saline
(1N). The cells were harvested by means of trypsinization
(0.25% Trypsin EDTA solution, Hi Media, India) and
checked for viability using trypan blue, sterility (Bactec,
USA) and counts in modiﬁed Neubauer chamber. For ﬂow
cytometric analysis of cells, CD 45(Per CP) negative and
CD90 (PE)/CD73 (PE) (Becton, Dickinson, USA) positive
tests were carried out. They were also stained by Giemsa and
further subjected to diﬀerentiation in to insulin-secreting
cells using diﬀerentiation medium with DMEM (glucose-
17.5mM), DMEM: F 12, Nicotinamide, Activin A, Exendin
4, Pentagastrin, hepatocyte growth factor, B-27, N-2 serum
supplement, and antibiotics. This cocktail upregulates gene
expression, nourishes the cells, and prevents their further
proliferation. No xenogenic material was used.
The cells were kept in this medium for 3 days for
diﬀerentiation and then subjected to isolation on Ficoll
Hypaque by density gradient.
3.4. Testing for Molecular Marker Characterization of Insulin
Secreting MSC. Cell pellet was then diluted with equal
amount of medium and after testing for sterility, viability,
and cell counts, subjected to immunoﬂuorescence test for
expression of transcription factors, paired box 6 (Pax-6),
marker for glucagon production, isl-1, key regulator for
normalisletcelldevelopment,whichisthegeneupregulating
expression of insulin, and pancreatic duodenal homeobox
gene (pdx-1) which is the regulator of β-cell speciﬁc gene
expression, function, and for self-renewal of β progenitor
cells [5, 6].
C-Peptide and Insulin. from supernatant of cultured cells
were measured by chemiluminescence.
3.5. Glucose Challenge Assay. Cells were further incubated in
6 well plates at the concentration of 5cells/cm sq. without
glucose, in glucose, (90 mM), 5mL, and 10mL respectively
for 2 hours and insulin and c-peptide levels were measured
at the end.
3.6. Culture of BM. The aspirated BM was subjected
to invitro expansion under self-designed medium usingStem Cells International 3
DMEM:F12 (1:1) with 20% human albumin, Erythropoi-
etin (V.H.B. Life Sciences, Inc, India), 10μL/100mL, G-CSF
(Gennova Biopharma, India), 10μL/100mL, Mitomycin C,
2μL/100mL,nonessentialaminoacids,1mL/100mL,Ascor-
bic acid, 10μL/100mL, and antibiotics in CO2 incubator at
37◦C with 5% CO2 under humid conditions. No xenogenic
material was used. Medium was replenished every other day
for 8 days.
3.7. Recipient Conditioning. Nonmyelo-ablative low-inten-
sity conditioning included target speciﬁc irradiation to
subdiaphragmatic lymph nodes, spleen, part of pelvic bones,
and lumbar vertebrae (200cGY × 5 days) from day −8
to −3 of transplantation. Anti-T cell antibody, 1.5mg/kg
BW and anti-B cell antibody, 6mg/kg BW were admin-
istered intravenously on days –2 and −1, respectively, to
prevent rejection and facilitate grafting of transplanted
cells. No immunosuppressive medication was used post-
transplantation.
3.8. Cell Transplantation. Cell cocktail was transplanted into
recipient on day 0 under general anesthesia as per our
own technique of omental cannulation by mini-laparotomy
in which a mid-line incision of 3cm was made 5cm
above umbilicus, omental vein was cannulated using 20
guage needle and cells were infused at the rate of 6–
8mL/min. Omental vein was ligated with silk after infusion,
hemostasischeckedandwoundclosedwithvicryl2/0stitches
and subcuticular stitches were taken using 3/0 monocryl
[7].
3.9. Posttransplant Patient Monitoring. Patients were moni-
tored closely for 4 hourly blood sugar levels for 3 days after
transplantation following 12 hourly monitoring for 1 week.
Fasting and postprandial (PP) blood sugar (BS) levels were
checked weekly for the 1st month and fortnightly for next
the 2 months. Serum c-peptide levels were measured daily
for the 1st week and with mixed meal tolerance weekly for
the 1st month. Insulin administration was made on sliding
scale with an objective of maintaining FBS <150mg% and
PPBS around 200mg%. Glutamic acid decarboxylase (GAD)
antibodiesweremonitoredbyELISAtechnique(Euroimmun
-Medizinische Labordiagnostika AG, UK) before and 3
months after infusion. Recipient monthly body weight, and
number of diabetic ketoacidosis (DKA) episodes were mon-
itored and evaluated before and after infusion. Glycosylated
hemoglobin(Hb1Ac)(referencerange:normal:<8.3%,good
control: 8.3 to 9%, fair control: 9-10%, poor control: >10%,
Erba diagnostics Mannheim, GmbH, Germany) levels were
measured at 2-month intervals post-transplantation.
Key endpoints of study were morbidity, mortality, unto-
ward side eﬀects from stem cell transplantation, and changes
in exogenous insulin requirements (daily dose/duration).
Secondary endpoints were serum C-peptide levels with
mixed-meal tolerance test at monthly intervals, GAD anti-
bodies and Hb1Ac following stem cell transplantation.
3.10. Patients. Eleven patients (7 males, 4 females) with
mean age 21.1 years (range: 13–43 years) with mean disease
duration of 8.2 years (range: 1–24 years) were subjected to
co-transplantation with IS-AD-MSC+HSCT. Seven out of
11 patients had associated DKA episodes (1 to 5 episodes).
Mean Hb1Ac levels were 8.47% (range: 6.2–10.3%) and
mean insulin requirement was 1.14units/kgBW/day (range:
0.42–2.4units per day).
4. Results
Donors were parents and siblings, in 4 patients cousin in 1,
and uncles in 2 patients.
4.1. Stem Cells. Mean total cell quantum transplanted was
96.3 mL (range: 92 to 118 mL) with nucleated cell counts of
CBM: 28×103/μL (range: 12.2 to 62.7×103/μL) and MSC-
1.2×103/μL(range:0.5t o2.1×103/μL),meanCD34+,0.62%
(range: 0.06 to 2.01%), mean CD 45−,9 0 +/73+ counts, and
39.99%(range:16.6to81.4%)/30.1%(range:14.1to65.7%).
All of them expressed transcription factors pax-6, pdx 1, and
isl-1 (Figure 2). Mean C-peptide level of cell inocula was
1.84ng/mL (range: 1.15–3.6ng/mL) and insulin level was
339.3μIU/L (range: 118 to 739μIU/L).
4.2. Patient Values. Mean pretransplant serum C-peptide
levels of 0.1ng/mL (range: 0.02 to 0.3ng/mL) increased
gradually to mean 0.37ng/mL (range: 0.1 to 1.8ng/mL)
(normal range: 0.7 to 1.9ng/mL by Monobind Inc, USA)
and mean pre-transplant exogenous insulin requirement
of 1.14units/kg BW/day (range: 0.42–2.1units/kg BW/day)
decreased to 0.63units/kg BW/day (range: 0.09–1unit/kg
BW/day) (Figure 3(a)). It was observed that there was
gradual fall in exogenous insulin requirement over the ﬁrst
2 to 4 months which then remained steady (Figure 3(b)).
Mean befor transplant Hb1Ac of 8.47 % (range: 6.22
to 10.3 %) decreased to 7.39 % (range: 5.72 to 8.98
%).
GAD antibodies between 10 and 210IU/mL in 5 patients
d e c r e a s e dt ov a l u e sb e t w e e n4t o1 8 0 I U / m La n di n3
patients where values were >2000IU/mL befor transplan-
tation remained the same. No functional correlation was
observed between insulin requirements/c-peptide levels and
GAD antibody levels.
4.3. Statistical Analysis. Insulin requirement, Hb1Ac, and
serum C-peptide levels were subjected to Student’s paired t-
test and change in insulin requirement was found to be the
most signiﬁcant with P = .009, Hb1Ac showed P = .03 and
c-peptide values showed P = .05.
Therewasnoadverse/untowardsideeﬀectrelatedtostem
cell infusion or administration of induction therapy. Over a
mean followup of 7.3 months (range: 2.2 months to 1 year)
all patients continued to have a feeling of well-being after
infusion and are physically more active, alert, on normal
vegetarian diet, and better rehabilitated in their professional
and personal lives. There was an impressive absence of DKA
episodes in all of them. Pretransplant weight of 54.6kg
(range: 23.5 to 82kg) increased marginally to 55.2kg (range:
25 to 82kg).4 Stem Cells International
Figure 2: Indirect immunoﬂuorescence demonstrating pax-6, isl-1, and pdx-1, from left to right, ×100.
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Figure 3: (a) Comparison of S.C-peptide levels and insulin requirement pre and post (7 months) stem cell transplantation. (b) Followup of
exogenous insulin requirement (units/KgBW/Day).
5. Discussion
Therapeutic strategies for addressing immune dysregulation
of IDDM include nonactivating monoclonal antibodies
against CD3, gene therapies, autologous HSCT, infusion
of dendritic cells, T-regulatory lymphocytes, umbilical cord
cells, embryonic or adult stem cells, and allogenic BM
transplantation [4, 6]. Invitro rodent models have shown
MSC derived from BM and spleen with capability of
insulin-secretion to treat hyperglycemia [8]. Human BM-
derived and adipose tissue-derived MSC have been found
to be phenotypically identical cell populations as those of
rodents [9]. We have generated in vitro MSC from human
adipose tissue which qualify the deﬁnition standardized
by the Mesenchymal and Tissue Stem Cell Committee of
the International Society for Cellular Therapy. MSC have
been deﬁned as the cells having plastic-adherence when
maintained under standard culture conditions, must have
the ability of osteogenic, adipogenic and chondrogenic
diﬀerentiation, must express CD73, CD90, and CD105, and
must lack expression of hematopoietic lineage markers c-
kit, CD14, CD34, CD 45, CD 11b, CD 29, CD79α,a n d
HLA-DR [10]. Our cells fulﬁll these criteria. We further
diﬀerentiated them to insulin secreting cells under deﬁned
culture conditions phenotypically identical to pancreatic β
cells [11]. These cells expressed transcription factors pdx-1,
pax-6, and isl-1, all three are central controlling genes
capable of reprogramming nonpancreatic cells to surrogate
β cell functions. Again our technique is a shortcut to
reprogramming non-pancreatic cells as compared to vector-
based gene transfer techniques [12].
Our results support the contention that combination of
these three transcription factors represents the establishment
of ectopic mechanisms to secrete insulin. These exciting
resultsraiseintriguingquestions;whetherthisdiﬀerentiation
involves epigenetic reprogramming, or nuclear content of
the MSC has become permissive to allow activation of this
transcription program for β cell function. Whatever may be
the reason this strategy has worked even in distantly related
cells of origin.Stem Cells International 5
6. Conclusion
This is the ﬁrst report of successfully treating IDDM with
co-transplantationofinsulin-secretingadiposetissuederived
MSC and HSCT. Easy and repeatable access to subcutaneous
adipose tissue provides a clear advantage over isolation of
MSC from BM. Isolation and culture techniques are simple
and easy to perform.
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